Amarin Corp. PLC Files 10-Q for Q1 2025
Ticker: AMRN · Form: 10-Q · Filed: May 7, 2025 · CIK: 897448
| Field | Detail |
|---|---|
| Company | Amarin Corp PLC\UK (AMRN) |
| Form Type | 10-Q |
| Filed Date | May 7, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-Q, financials, pharmaceuticals
Related Tickers: AMRN
TL;DR
Amarin's Q1 2025 10-Q is in. Check financials for latest updates.
AI Summary
Amarin Corp. plc filed its 10-Q for the period ending March 31, 2025. The company's financial statements indicate various financial activities and disclosures relevant to its operations in the pharmaceutical sector. Specific details on revenue, expenses, and other financial metrics are provided within the filing.
Why It Matters
This filing provides investors and stakeholders with a quarterly update on Amarin's financial health and operational performance, crucial for evaluating the company's current standing and future prospects.
Risk Assessment
Risk Level: medium — As a pharmaceutical company, Amarin faces inherent risks related to drug development, regulatory approvals, and market competition, which are reflected in its financial reporting.
Key Numbers
- N/A — Revenue (Specific revenue figures for the quarter are not directly extracted but are detailed within the 10-Q.)
- N/A — Net Income/Loss (Specific net income or loss figures for the quarter are not directly extracted but are detailed within the 10-Q.)
- N/A — Total Assets (Total assets as of March 31, 2025, are detailed within the 10-Q.)
Key Players & Entities
- AMARIN CORP PLC\UK (company) — Filer
- 20250331 (date) — Period of Report
- 20250507 (date) — Filing Date
- Vascepa (product) — Key Product Mentioned
- Biologix (company) — Mentioned Entity
- CslSeqirus (company) — Mentioned Entity
- HLSTherapeuticsIncorp (company) — Mentioned Entity
FAQ
What is the reported net income or loss for Amarin Corp. plc for the quarter ended March 31, 2025?
The 10-Q filing for the period ending March 31, 2025, contains detailed financial statements that would report the net income or loss for the quarter.
What were the total revenues for Amarin Corp. plc in the first quarter of 2025?
The filing for the period ending March 31, 2025, includes the consolidated statements of operations which would specify the total revenues generated during the quarter.
Are there any significant updates regarding the company's key product, Vascepa, in this filing?
The filing mentions 'Vascepa' and related terms, indicating its continued relevance to the company's operations, with specific details likely found in the business or risk factors sections.
What is the company's cash and cash equivalents balance as of March 31, 2025?
The balance sheet included in the 10-Q filing for the period ending March 31, 2025, would provide the exact figure for cash and cash equivalents.
Does the filing mention any new partnerships or licensing agreements?
The filing references 'OutLicensesAgreement' and mentions entities like 'Biologix' and 'CslSeqirus', suggesting potential activities related to licensing or partnerships.
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on May 7, 2025 regarding AMARIN CORP PLC\UK (AMRN).